J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

While AkzoNobel is one of the most diversified paint and coatings producers, it has somewhat focused its portfolio in recent years, exemplified by the sale of its specialty chemical business.

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

This Fool considers how two low-risk and well-established FTSE shares could offer stability and growth during a period of market volatility.

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Top investment firms expect non-US stocks to outperform. Here are Morningstar’s top international stock and ETF picks today.

The stock market can be a scary place for those who aren’t prepared. Our writer outlines three ways we might avoid getting ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other cheapest stocks ...